ITGA9 and rhabdomyosarcoma: Herein, we describe the anti-metastatic effects of the genetic inhibition of ITGA9 in two different cancers: rhabdomyosarcoma (RMS), the most prevalent soft tissue sarcoma in children [23], and neuroblastoma (NB), the most common extracranial solid tumour in children [24].